Cancer Family
Neuroepithelial Neoplasm
CI-CAN-00000287Explore in graph →
Non-malignant811 active trials6 approved drugs154 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000287Explore in graph →
Clinical trials
2,935 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07447531 | T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas | recruiting | N/A | 15 | John M. BuattiOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04425434 | Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma(GFARB12019) | recruiting | — | 3,000 | French Africa Pediatric Oncology GroupOTHER | 6 | Mar 2, 2026 |
| clinicaltrials |
| NCT06719440 | Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume(BELGICA) | recruiting | N/A | 347 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07236840 | Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors(NEMO) | recruiting | — | 600 | Tata Memorial CentreOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07405372 | Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of Gliomas | recruiting | — | 10 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06058988 | Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07426848 | OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour Patients(OTSMILE) | recruiting | N/A | 96 | Royal College of Surgeons, IrelandOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05345002 | All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma | recruiting | Phase 2 | 55 | Stephen Bagley, MD, MSCEOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07318818 | A Clinical Trial of P134 Cells in Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 26 | Tasly Pharmaceutical Group Co., LtdINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04765514 | Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients | recruiting | Phase 2 | 107 | AHS Cancer Control AlbertaOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06222138 | Study of Biologic Tumor and Plasma Biomarkers of Response to TTFields in Patients Treated for Newly Diagnosed Glioblastoma(EXOFIELDS) | recruiting | N/A | 80 | Institut Claudius RegaudOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07263438 | Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial(Phenix) | recruiting | Phase 2 | 59 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06132685 | Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial | recruiting | Phase 2 | 200 | Emory UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05139277 | Evaluation of the CONVIVO System | recruiting | N/A | 30 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT06650163 | Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors | recruiting | Phase 1 | 20 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07391215 | 5G-PEARL: Paxalisib in Malignant Brain Tumours(5G-PEARL) | recruiting | Phase 1 / Phase 2 | 64 | Institute of Cancer Research, United KingdomOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05653622 | Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma(SIB-DOPA) | recruiting | Phase 2 | 75 | Centre Paul StraussOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05653635 | Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study(ReciDOPA) | recruiting | Phase 2 | 54 | Centre Paul StraussOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05756985 | Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue | recruiting | — | 120 | Baptist Health South FloridaOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05331521 | A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).(ImproveCodel) | recruiting | Phase 3 | 406 | University Hospital HeidelbergOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT06470711 | Mapping of Electrical Properties in the Brain | recruiting | — | 120 | Mayo ClinicOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT02394626 | Surgery for Recurrent Glioblastoma(RESURGE) | recruiting | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 9 | Feb 2, 2026 | clinicaltrials |
| NCT05464992 | Use of CEST (Chemical Exchange Saturation Transfer) Imaging in PET/MRI(GlioCEST) | recruiting | N/A | 800 | Centre Paul StraussOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT05683808 | Venous Thromboembolism Prevention in Outpatients With Glioma(VTE-POG) | recruiting | Phase 2 | 40 | University of Vermont Medical CenterOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT04702581 | A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery(POLO) | recruiting | Phase 3 | 280 | Hospices Civils de LyonOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05762419 | FUS Etoposide for DMG | recruiting | Phase 1 | 10 | Columbia UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04865315 | A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors(HiLoGlio) | recruiting | — | 50 | Maastricht Radiation OncologyOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT04196413 | GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG) | recruiting | Phase 1 | 97 | Stanford UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07364786 | Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma(AFGBMBiop) | recruiting | Phase 2 | 10 | Peter SiesjöOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05084430 | Study of Pembrolizumab and M032 (NSC 733972) | recruiting | Phase 1 / Phase 2 | 28 | University of Alabama at BirminghamOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07143812 | A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma | recruiting | Phase 1 | 10 | CHA UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06630260 | 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours(5G-RUBY) | recruiting | Phase 1 / Phase 2 | 182 | Institute of Cancer Research, United KingdomOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06625684 | Key Longitudinal Associations With Risk and Glioblastoma Outcomes(Key LARGO) | recruiting | — | 200 | Duke UniversityOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT03144167 | Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy(SPECTROBEVA) | recruiting | N/A | 170 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05465954 | Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma | recruiting | Phase 2 | 54 | Mayo ClinicOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05083754 | Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma | recruiting | Phase 1 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05106296 | Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | recruiting | Phase 1 | 37 | Theodore S. JohnsonOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05669820 | Antisecretory Factor Glioblastoma Phase 2(AFGB2) | recruiting | Phase 2 / Phase 3 | 300 | Peter SiesjöOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07240662 | Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma(VIOLETA) | recruiting | — | 150 | iOMEDICO AGINDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT02358187 | A Vaccine Trial for Low Grade Gliomas | recruiting | Phase 2 | 25 | James FelkerOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03267459 | Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma?(PREDIR) | recruiting | — | 60 | Fondation Ophtalmologique Adolphe de RothschildNETWORK | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05049148 | Platelets Activation in Brain Neoplasms(Platon) | recruiting | N/A | 50 | Fondation Ophtalmologique Adolphe de RothschildNETWORK | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06717295 | The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling(CCANED-CIPHER) | recruiting | — | 6,000 | Javier ToledoINDUSTRY | 3 | Jan 2, 2026 | clinicaltrials |
| NCT06829173 | Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas | recruiting | Early Phase 1 | 39 | NYU Langone HealthOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07093814 | A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma | recruiting | Phase 1 / Phase 2 | 42 | Guangzhou Virotech Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06645808 | PET-imaging of Two Vartumabs in Patients With Solid Tumors(VARTUTRACE) | recruiting | Early Phase 1 | 32 | Var2 PharmaceuticalsINDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT07306299 | A Phase I Clinical Trial of a mRNA Vaccine for Recurrent or Progressive High-grade Glioma | recruiting | Phase 1 | 10 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT05423210 | Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme | recruiting | Early Phase 1 | 12 | Stony Brook UniversityOTHER | 1 | Dec 22, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 3, 2026source: clinicaltrials